Form 8-K - Current report:
SEC Accession No. 0001558370-25-005275
Filing Date
2025-04-23
Accepted
2025-04-23 16:30:27
Documents
13
Period of Report
2025-04-21
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20250421x8k.htm   iXBRL 8-K 39013
  Complete submission text file 0001558370-25-005275.txt   160468

Data Files

Seq Description Document Type Size
2 EX-101.SCH plx-20250421.xsd EX-101.SCH 3633
3 EX-101.LAB plx-20250421_lab.xml EX-101.LAB 16017
4 EX-101.PRE plx-20250421_pre.xml EX-101.PRE 10762
15 EXTRACTED XBRL INSTANCE DOCUMENT plx-20250421x8k_htm.xml XML 4864
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 25862007
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)